Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 2
2011 2
2012 1
2013 3
2014 1
2015 1
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Telmisartan, ramipril, or both in patients at high risk for vascular events.
ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET Investigators, et al. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378520 Free article. Clinical Trial.
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
Cowan BR, Young AA, Anderson C, Doughty RN, Krittayaphong R, Lonn E, Marwick TH, Reid CM, Sanderson JE, Schmieder RE, Teo K, Wadham AK, Worthley SG, Yu CM, Yusuf S, Jennings GL; ONTARGET Investigators. Cowan BR, et al. Am J Cardiol. 2009 Dec 1;104(11):1484-9. doi: 10.1016/j.amjcard.2009.07.018. Epub 2009 Oct 14. Am J Cardiol. 2009. PMID: 19932779 Clinical Trial.
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).
Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Böhm M, Williams B, Yusoff K, Teo K, Yusuf S; ONTARGET Investigators. Redon J, et al. J Am Coll Cardiol. 2012 Jan 3;59(1):74-83. doi: 10.1016/j.jacc.2011.09.040. J Am Coll Cardiol. 2012. PMID: 22192672 Free article. Clinical Trial.
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators. Mann JF, et al. Lancet. 2008 Aug 16;372(9638):547-53. doi: 10.1016/S0140-6736(08)61236-2. Lancet. 2008. PMID: 18707986 Clinical Trial.
12 results